Base period - PSC: AN12 research and development services
Ended Definitive Contract Awarded Last action
- Contract number
- HDTRA114C0115
- Awardee
-
Mapp Biopharmaceutical, Inc. UEI M9V9QTHR1H28
- Awarding agency
-
Defense Contract Management Agency
Department of Defense
- Obligated
- $6,173,324
Award facts
- Contract value 100% obligated
- $6,173,324.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Defense Threat Reduction Agency Department of Defense
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 8 offers Basic Research
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | -$56,733 | |
| Funding Only Action | $1,200,000 | |
| Exercise an Option | $200,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $1,128,981 | |
| Exercise an Option | $1,128,981 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $2,572,095 |
Show all 11
About this award
This is a federal contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in the development of antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, valued at $6,173,324.00, is for research and development services during the base period, with a period of performance ending on August 31, 2017. The contract is a Cost Plus Fixed Fee Definitive Contract, and there is no set-aside designation for this award. This contract is part of Mapp Biopharmaceutical's broader engagement with the U.S. government, which includes multiple contracts and grants from agencies such as the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) and the U.S. Army's Research, Development and Engineering Command, focused on the development of medical countermeasures for infectious diseases, including Ebola, Sudan, Marburg, and botulinum neurotoxin.
Quick answers
Who was awarded contract HDTRA114C0115?
HDTRA114C0115 was awarded to Mapp Biopharmaceutical, Inc. by Defense Contract Management Agency (Department of Defense) on June 10, 2014.
How much is contract HDTRA114C0115 worth?
The government has obligated $6,173,324 on HDTRA114C0115.
Which agency awarded contract HDTRA114C0115?
Defense Contract Management Agency (Department of Defense) awarded HDTRA114C0115, with funding from Defense Threat Reduction Agency (Department of Defense).
Was contract HDTRA114C0115 competed?
The extent of competition for HDTRA114C0115 was full and open competition. The government received 8 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award